Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2945737 | 0.87 | MEN1 (0.53) | KMT2AMEN1LMNAGAAHTT | |
| SCHEMBL2255527 | 0.82 | MEN1 (0.52) | KMT2AMEN1LMNAGAAHTT | |
| SCHEMBL2257606 | 0.82 | LMNA (0.56) | KMT2AMEN1LMNAGAAHTT | |
| SCHEMBL2450713 | 0.81 | MEN1 (0.48) | KMT2AMEN1LMNAGAAALDH1A1 | |
| SCHEMBL14518843 | 0.80 | KMT2A (0.34) | KMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL12302991 | 0.80 | DGAT1 (0.34) | LMNAALDH1A1 | |
| SCHEMBL8082109 | 0.79 | NPC1 (0.59) | KMT2AMEN1LMNAGAAHTT | |
| SCHEMBL2255114 | 0.76 | HIF1A (0.48) | KMT2AMEN1LMNAGAAHTT | |
| SCHEMBL12303006 | 0.76 | DGAT1 (0.32) | LMNAALDH1A1 | |
| SCHEMBL2452481 | 0.73 | POLB (0.43) | KMT2AMEN1ALDH1A1HPGDPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017603-B2 | Pyrimido [4,5-B]-oxazines for use as DGAT inhibitors | ASTRAZENECA AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-20100311737-A1 | PYRIMIDO [4,5-B] -OXAZINES FOR USE AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | disclosed |
| US-7749997-B2 | Pyrimido [4,5-B] -Oxazines for use as DGAT inhibitors | ASTRAZENECA AB (CH) | 2010-07-06 | — | — | US | disclosed |
| US-20080306059-A1 | Acyl CoA:diacylglycerol acyltransferase (DGAT) inhibitors such as 4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]bicyclo[2.2.2]oct-1-yl}acetic acid, useful for the treatment of non-insulin dependent diabetes, insulin resistance, impaired glucose tolerance and obesity in humans | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311737-A1 | PYRIMIDO [4,5-B] -OXAZINES FOR USE AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | KMT2A 1484/4885MEN1 3611/4885LMNA 4712/4885 |
| US-20080306059-A1 | Acyl CoA:diacylglycerol acyltransferase (DGAT) inhibitors such as 4-[4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl]bicyclo[2.2.2]oct-1-yl}acetic acid, useful for the treatment of non-insulin dependent diabetes, insulin resistance, impaired glucose tolerance and obesity in humans | DGAT1, DGAT2, ACAT2 | KMT2A 688/4885MEN1 4450/4885LMNA 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.